The 5-point MACE data is solid in my opinion. The biggest concern is how will this tranlsate to MACE reduction on the more strict 3-point MACE scale? In my opinion, the post-hoc analyses for 5-point MACE and IVUS in the total population and various subgroups (low-HDL, lipitor vs. crestor, statin dose, high baseline CRP, chronic kidney disease, diabetes), especially in the context of the multi-modal beneficial effects of RVX-208 on apoAI/HDL, complement cascade, coagulation cascade, inflammation and glucose metabolism, justify the hypothesis set forth for Phase III BETonMACE to reduce cardiovascular death, stroke and myocardial infarction (3-point MACE).

BearDownAZ